Literature DB >> 28061688

Aptamers as Therapeutics.

Shahid M Nimjee1, Rebekah R White2, Richard C Becker3, Bruce A Sullenger2,4.   

Abstract

Aptamers are single-stranded nucleic acid molecules that bind to and inhibit proteins and are commonly produced by systematic evolution of ligands by exponential enrichment (SELEX). Aptamers undergo extensive pharmacological revision, which alters affinity, specificity, and therapeutic half-life, tailoring each drug for a specific clinical need. The first therapeutic aptamer was described 25 years ago. Thus far, one aptamer has been approved for clinical use, and numerous others are in preclinical or clinical development. This review presents a short history of aptamers and SELEX, describes their pharmacological development and optimization, and reviews potential treatment of diseases including visual disorders, thrombosis, and cancer.

Entities:  

Keywords:  SELEX; antidote; aptamer; pharmacology; therapeutics

Mesh：

Substances：

Year:  2017        PMID： 28061688      PMCID： PMC6035745          DOI： 10.1146/annurev-pharmtox-010716-104558

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN： 0362-1642            Impact factor:   13.820


  103 in total

1.  Near-infrared light-triggered, targeted drug delivery to cancer cells by aptamer gated nanovehicles.

Authors:  Xinjian Yang; Xia Liu; Zhen Liu; Fang Pu; Jinsong Ren; Xiaogang Qu
Journal:  Adv Mater       Date:  2012-04-27       Impact factor: 30.849

2.  Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.

Authors:  James O McNamara; Eran R Andrechek; Yong Wang; Kristi D Viles; Rachel E Rempel; Eli Gilboa; Bruce A Sullenger; Paloma H Giangrande
Journal:  Nat Biotechnol       Date:  2006-06-25       Impact factor: 54.908

3.  Liposome-anchored vascular endothelial growth factor aptamers.

Authors:  M C Willis; B D Collins; T Zhang; L S Green; D P Sebesta; C Bell; E Kellogg; S C Gill; A Magallanez; S Knauer; R A Bendele; P S Gill; N Janjić; B Collins
Journal:  Bioconjug Chem       Date:  1998 Sep-Oct       Impact factor: 4.774

4.  Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery.

Authors:  Jianwei Guo; Xiaoling Gao; Lina Su; Huimin Xia; Guangzhi Gu; Zhiqing Pang; Xinguo Jiang; Lei Yao; Jun Chen; Hongzhuan Chen
Journal:  Biomaterials       Date:  2011-07-23       Impact factor: 12.479

5.  Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen.

Authors:  Shawn E Lupold; Brian J Hicke; Yun Lin; Donald S Coffey
Journal:  Cancer Res       Date:  2002-07-15       Impact factor: 12.701

6.  Potent 2'-amino-2'-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor.

Authors:  D Jellinek; L S Green; C Bell; C K Lynott; N Gill; C Vargeese; G Kirschenheuter; D P McGee; P Abesinghe; W A Pieken
Journal:  Biochemistry       Date:  1995-09-12       Impact factor: 3.162

7.  Targeted inhibition of prostate cancer metastases with an RNA aptamer to prostate-specific membrane antigen.

Authors:  Justin P Dassie; Luiza I Hernandez; Gregory S Thomas; Matthew E Long; William M Rockey; Craig A Howell; Yani Chen; Frank J Hernandez; Xiu Ying Liu; Mary E Wilson; Lee-Ann Allen; Daniel A Vaena; David K Meyerholz; Paloma H Giangrande
Journal:  Mol Ther       Date:  2014-06-23       Impact factor: 11.454

Review 8.  Fit for the Eye: Aptamers in Ocular Disorders.

Authors:  Daniel W Drolet; Louis S Green; Larry Gold; Nebojsa Janjic
Journal:  Nucleic Acid Ther       Date:  2016-01-12       Impact factor: 5.486

9.  Targeting Axl with an high-affinity inhibitory aptamer.

Authors:  Laura Cerchia; Carla L Esposito; Simona Camorani; Anna Rienzo; Loredana Stasio; Luigi Insabato; Andrea Affuso; Vittorio de Franciscis
Journal:  Mol Ther       Date:  2012-08-21       Impact factor: 11.454

10.  A Synthetic Aptamer-Drug Adduct for Targeted Liver Cancer Therapy.

Authors:  Thu Le Trinh; Guizhi Zhu; Xilin Xiao; William Puszyk; Kwame Sefah; Qunfeng Wu; Weihong Tan; Chen Liu
Journal:  PLoS One       Date:  2015-11-02       Impact factor: 3.240
View more
  112 in total

Review 1.  Strategies to Modulate MicroRNA Functions for the Treatment of Cancer or Organ Injury.

Authors:  Tae Jin Lee; Xiaoyi Yuan; Keith Kerr; Ji Young Yoo; Dong H Kim; Balveen Kaur; Holger K Eltzschig
Journal:  Pharmacol Rev       Date:  2020-07       Impact factor: 25.468

Review 2.  Emerging Paradigm of Intracellular Targeting of G Protein-Coupled Receptors.

Authors:  Madhu Chaturvedi; Justin Schilling; Alexandre Beautrait; Michel Bouvier; Jeffrey L Benovic; Arun K Shukla
Journal:  Trends Biochem Sci       Date:  2018-05-04       Impact factor: 13.807

Review 3.  [Andrological consultation in new systemic oncological therapies with small molecules].

Authors:  Till Weidner; Uwe Paasch; Sonja Grunewald
Journal:  Hautarzt       Date:  2018-12       Impact factor: 0.751

4.  Duplex RNAs and ss-siRNAs Block RNA Foci Associated with Fuchs' Endothelial Corneal Dystrophy.

Authors:  Jiaxin Hu; Xiulong Shen; Frank Rigo; Thahza P Prakash; V Vinod Mootha; David R Corey
Journal:  Nucleic Acid Ther       Date:  2019-01-24       Impact factor: 5.486

5.  An in Vitro Selection Strategy Identifying Naked DNA That Localizes to Cell Nuclei.

Authors:  John Smestad; Brandon Wilbanks; Louis J Maher
Journal:  J Am Chem Soc       Date:  2019-11-12       Impact factor: 15.419

6.  Aptamer-Engineered Natural Killer Cells for Cell-Specific Adaptive Immunotherapy.

Authors:  Shuanghui Yang; Jianguo Wen; Huan Li; Ling Xu; Yanting Liu; Nianxi Zhao; Zihua Zeng; Jianjun Qi; Wenqi Jiang; Wei Han; Youli Zu
Journal:  Small       Date:  2019-04-26       Impact factor: 13.281

7.  Tethered imidazole mediated duplex stabilization and its potential for aptamer stabilization.

Authors:  Lars Verdonck; Dieter Buyst; Anne-Mare de Vries; Vicky Gheerardijn; Annemieke Madder; José C Martins
Journal:  Nucleic Acids Res       Date:  2018-12-14       Impact factor: 16.971

8.  Therapeutic Aptamers: Evolving to Find their Clinical Niche.

Authors:  Shahid M Nimjee; Bruce A Sullenger
Journal:  Curr Med Chem       Date:  2020       Impact factor: 4.530

9.  Aptamers as Reversible Sorting Ligands for Preparation of Cells in Their Native State.

Authors:  Bethany Powell Gray; Martin D Requena; Michael D Nichols; Bruce A Sullenger
Journal:  Cell Chem Biol       Date:  2019-12-23       Impact factor: 8.116

10.  Several structural motifs cooperate in determining the highly effective anti-thrombin activity of NU172 aptamer.

Authors:  Romualdo Troisi; Valeria Napolitano; Vera Spiridonova; Irene Russo Krauss; Filomena Sica
Journal:  Nucleic Acids Res       Date:  2018-12-14       Impact factor: 16.971
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.